COVID-19 in severe asthma treated with omalizumab: The Maltese perspective
Open Access
- 14 September 2021
- journal article
- research article
- Published by E.U. European Publishing in Pneumon
- Vol. 34 (3), 1-6
- https://doi.org/10.18332/pne/141591
Abstract
Introduction: SARS-CoV-2 was identified as the causative agent of the COVID-19 pandemic, which has been the focus of extensive research for over a year. Asthmatics were listed as a high-risk group for susceptibility to SARS-CoV-2. Several hypotheses have been proposed regarding protective...Keywords
This publication has 30 references indexed in Scilit:
- COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and CorticosteroidsAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Risk factors for severity and mortality in adult COVID-19 inpatients in WuhanJournal of Allergy and Clinical Immunology, 2020
- Omalizumab and COVID‐19 treatment: Could it help?Dermatologic Therapy, 2020
- A Cohort of Patients with COVID-19 in a Major Teaching Hospital in EuropeJournal of Clinical Medicine, 2020
- Does asthma affect morbidity or severity of COVID-19?Journal of Allergy and Clinical Immunology, 2020
- Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?The Lancet. Respiratory Medicine, 2020
- Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epitheliumPublished by Cold Spring Harbor Laboratory ,2020
- Diabetes is a risk factor for the progression and prognosis of COVID‐19Diabetes/Metabolism Research and Reviews, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, ChinaAllergy, 2020